UnknownPhase 2NCT00936533

Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita

Studying Epidermolysis bullosa simplex

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Uppsala University
Principal Investigator: Carl Swartling
Uppsala University
Intervention: Dysport® (Botulinumtoxin A (Btx A))(drug)
Enrollment: 40 enrolled
Eligibility: 16 years · All sexes
Timeline: 2009 – 2012

Study locations (1)

Svettmottagningen, Sofiahemmet, Stockholm, Sweden

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00936533 on ClinicalTrials.gov

Other trials for Epidermolysis bullosa simplex

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT06136403
A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
Centre Hospitalier Universitaire de Nice

See all trials for Epidermolysis bullosa simplex →

← Back to all trials